680214-97-5

Upstream product

• 333-20-0 potassium thioacyanate 
• 1710-98-1 p-tert-butyl benzoyl chloride 
• 98-73-7 4-(1,1-dimethylethyl)benzoic acid 
• 540-72-7 sodium thiocyanide 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 1070956-11-4 4-tert-butyl-N-{4-[5-(4-chloro-phenoxy)-pentyloxy]-2,3-dihydro-indole-1-carbothioyl}-benzamide 
• 1332220-30-0 N-((4-amino-2-chlorophenyl)thiocarbamoyl)-4-(tert-butyl)benzamide 
• 1332220-31-1 4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]carbamothioyl]benzamide 
• 364627-39-4 4-tert-butyl-N-[(2-chloro-4-nitro-phenyl)carbamothioyl] benzamide 
• 1332219-97-2 4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)-carbamothioyl]benzamide 
• 1332220-36-6 tert-butyl N-[5-[(4-tert-butylbenzoyl)carbamothioylamino]-2-[(2-chlorobenzoyl) amino] phenyl]-carbamate 
• 1332220-32-2 tert-butyl N-[4-[(4-tert-butylbenzoyl)carbamothioylamino]-2-methoxy-phenyl] carbamate 
• 1384385-23-2 C₂₃H₂₄N₄OS*ClH 
• 1332220-04-8 4-tert-butyl-N-[[4-(3-pyridylamino)phenyl]-carbamothioyl]benzamide hydrochloride 
• 1332220-00-4 4-tert-butyl-N-[(2-chloro-3-methyl-phenyl)-carbamothioyl]benzamide 
• 642981-83-7 4-tert-butyl-N-[(3-methoxyphenyl)-carbamothioyl]benzamide 
• 791795-15-8 4-tert-butyl-N-[(2-methoxyphenyl)-carbamothioyl]benzamide 
• 496031-64-2 4-tert-butyl-N-(p-tolylcarbamothioyl)-benzamide 
• 1332220-22-0 N-[(3-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide 

Relevant academic research and scientific papers

Synthesis and anti(myco)bacterial activity of novel 5,5-diphenylpyrrolidine N-aroylthiourea derivatives and a functionalized hexahydro-1H-pyrrolo[1,2-c]imidazole

In this paper, five novel 5,5-diphenylpyrrolidine N-aroylthiourea derivatives were synthesized by stereoselective cycloaddition of N-diphenylmethylene-protected glycine methyl ester and methyl acrylate, and subsequent coupling with aroylisothiocyanates. The cis-stereochemistry of one of the heterocyclic thiourea derivatives was characterized by single crystal X-ray diffraction studies. The compounds showed antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Aeromonas hydrophila, Escherichia. coli and Acinetobacter baumannii with minimum inhibitory concentration values in the range of 62.5–1000 μg/mL against these bacterial strains. Antimycobacterial activity of the compounds was investigated against the M. tuberculosis H37Rv strain and all compounds exhibited antimycobacterial activity with a minimum inhibitory concentration value of 80 μg/mL. Additionally, methyl 5,5-diphenylhexahydro-1-oxo-3-thioxo-1H-pyrrolo[1,2-c]imidazole-6-carboxylate was synthesized by cyclization reaction of the 5,5-diphenylpyrrolidine N-aroylthiourea derivatives in the presence of hydrazine monohydrate and exhibited antibacterial activity with a minimum inhibitory concentration value of 62.5 μg/mL against the same bacterial strains and exhibited antimycobacterial activity with a minimum inhibitory concentration value of 80 μg/mL against the M. tuberculosis H37Rv strain.

Application of acylthiourea compound in preparation of medicines for resisting enterovirus

The invention discloses an application of an acylthiourea compound in preparation of an anti-enterovirus drug, and belongs to the technical field of medicines. The structure of the acylthiourea compound of the present invention is as shown in the general

Design, synthesis and biological evaluation of B-region modified diarylalkyl amide analogues as novel TRPV1 antagonists

Design, synthesis and biological evaluation of B-region, known to be a dipolar interacting pharmacophore, modified diarylalkyl amide analogues for novel TRPV1 (transient receptor potential channel, vanilloid subfamily member 1) antagonists was described. A variety of moieties including guanidines, heterocyclic rings, cinnamides, and α-substituted acetamides were introduced at the B-region. TRPV1 antagonistic activities of these analogues were evaluated by 45Ca2+ uptake assay in rat DRG neuron. In particular, α,α-difluoroamide 53 exhibited 3-fold more potent TRPV1 antagonistic activity (IC50 = 0.058 μM) than the parent amide analogue 6.

NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT

Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Hav

NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT

Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Hav

INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS

Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutical

Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors

An efficient synthetic methodology to provide indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives is described. These conformationally restricted heterobicyclic scaffolds were evaluated as a novel class of HCV inhibitors. Introduction of an acyl group at the NH2 of the thiourea moiety has been found to enhance inhibitory activity. The chain length and the position of the alkyl group on the indoline aromatic ring markedly influenced anti-HCV activity. The indoline scaffold was more potent than the corresponding indole and tetrahydroquinoline scaffolds and analogue 31 displayed excellent activity (EC50 = 510 nM) against HCV without significant cytotoxicity (CC50 >50 μM).

On the Preparation of Substituted 4H-1,3,4-Thiadiazolo[2,3-c]-1,2,4-triazin-4-ones and 1,2,4-Triazolo[3,4-b]-1,3,4-thiadiazoles

The reaction of benzoyl isothiocyanates and methoxycarbonyl isothiocyanate with 4-amino-4,5-dihydro-3-(methylthio)-1,2,4-triazin-5-ones in acetonitrile gave several substituted 4H-1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-ones VIa-h instead of the expected